Form 8-K - Current report:
SEC Accession No. 0001564590-22-013226
Filing Date
2022-04-01
Accepted
2022-04-01 16:02:36
Documents
12
Period of Report
2022-03-31
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K ubx-8k_20220331.htm   iXBRL 8-K 28186
  Complete submission text file 0001564590-22-013226.txt   156748

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ubx-20220331.xsd EX-101.SCH 5714
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ubx-20220331_lab.xml EX-101.LAB 19419
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ubx-20220331_pre.xml EX-101.PRE 11595
6 EXTRACTED XBRL INSTANCE DOCUMENT ubx-8k_20220331_htm.xml XML 3559
Mailing Address 3280 BAYSHORE BOULEVARD BRISBANE CA 94005
Business Address 3280 BAYSHORE BOULEVARD BRISBANE CA 94005 (415) 328-5504
Unity Biotechnology, Inc. (Filer) CIK: 0001463361 (see all company filings)

EIN.: 264726035 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38470 | Film No.: 22798146
SIC: 2834 Pharmaceutical Preparations